Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation

Liver International

Volumn 35, Issue 12, 2015, Pages 2530-2536

  Yoo, Jeong Ju ^a   Cho, Eun Ju ^a   Cho, Young Youn ^a   Lee, Minjong ^a   Lee, Dong Hyeon ^a   Cho, Yuri ^a   Lee, Jeong Hoon ^a   Yu, Su Jong ^a   Yoon, Sung Soo ^a   Yoon, Jung Hwan ^a   Kim, Yoon Jun ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Hematopoietic stem cell transplantation; Prophylaxis; Reactivation

Indexed keywords

ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIGEN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL PROPHYLAXIS; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOTHERAPY; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT MONITORING; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK REDUCTION; SHORT COURSE THERAPY; VIRUS REACTIVATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BLOOD; CHEMOPROPHYLAXIS; COMPLICATION; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; PHYSIOLOGY; PROCEDURES; SECONDARY PREVENTION; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 84983127165     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12882     Document Type: Article

References (14)

1. Lok AS, Mcmahon BJ . Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
2. Lee IC, Huang YH, Chu CJ, et al. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 2010; 73: 156-60.
3. Wu JM, Huang YH, Lee PC, Lin HC, Lee SD . Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 2009; 43: 496-8.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
5. Kusumoto S, Tanaka Y, Mizokami M, Ueda R . Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
6. Yeo W, Johnson PJ . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
7. Hwang JP, Lok AS . Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 209-19.
8. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-53.
9. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
10. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-72.
11. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
12. Ikeda M . Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol 2013; 43: 8-16.
13. Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepatitis 2010; 17: 807-15.
14. Vigano M, Vener C, Lampertico P, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 125-31.